y 27632 has been researched along with ccg-203971 in 1 studies
| Studies (y 27632) | Trials (y 27632) | Recent Studies (post-2010) (y 27632) | Studies (ccg-203971) | Trials (ccg-203971) | Recent Studies (post-2010) (ccg-203971) |
|---|---|---|---|---|---|
| 1,924 | 3 | 891 | 5 | 0 | 5 |
| Protein | Taxonomy | y 27632 (IC50) | ccg-203971 (IC50) |
|---|---|---|---|
| Transforming protein RhoA | Homo sapiens (human) | 5.85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bell, JL; Haak, AJ; Kirchhoff, PD; Larsen, SD; Neubig, RR; Wade, SM | 1 |
1 other study(ies) available for y 27632 and ccg-203971
| Article | Year |
|---|---|
Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents.
Topics: Amides; Anilides; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Neoplasm Metastasis; Nipecotic Acids; Oncogene Proteins, Fusion; Prostatic Neoplasms; rhoA GTP-Binding Protein; Serum Response Factor; Structure-Activity Relationship; Trans-Activators | 2013 |